4DMedical
4DMedical is a global medical technology company aiming to change the outcome for patients with lung disease by revolutionizing respiratory imaging and ventilation analysis.
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor | €0.0 | round | |
| N/A | €0.0 | round | |
* | AUD10.0m | Post IPO Debt | |
| Total Funding | 000k | ||
Monash University(exited)
| AUD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 386 % | (73 %) | 981 % | 198 % | 158 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (8313 %) | (3344 %) | (10123 %) | (1045 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (9872 %) | (2333 %) | (11149 %) | (1180 %) | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 1087 % | - | 1430 % | 23 % | - | - |
Source: Company filings or news article, Equity research estimates
